All Relations between Alzheimer Disease and cannabinoids

Publication Sentence Publish Date Extraction Date Species
Giovanna Giuseppina Altobelli, Donatella Cimini, Giuseppe Esposito, Teresa Iuvone, Vincenzo Cimin. Analysis of calretinin early expression in the rat hippocampus after beta amyloid (1-42) peptide injection. Brain research. vol 1610. 2016-02-09. PMID:25813826. we carried out quantitative analysis of the transient changes in calretinin expression shown by hybridochemistry within neuronal cell populations in the hippocampus of a beta amyloid-treated rat model of alzheimer's disease and their correlation with endocannabinoid increase. 2016-02-09 2023-08-13 rat
Diana Aguirre-Rueda, Sol Guerra-Ojeda, Martin Aldasoro, Antonio Iradi, Elena Obrador, Maria D Mauricio, Jose M Vila, Patricia Marchio, Soraya L Valle. WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture. PloS one. vol 10. issue 4. 2016-01-11. PMID:25874692. further studies would be needed to assess the possible beneficial effects of cannabinoids in alzheimer's disease patients. 2016-01-11 2023-08-13 human
Javier Fernández-Ruiz, Julián Romero, José A Ramo. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others. Handbook of experimental pharmacology. vol 231. 2015-12-16. PMID:26408163. we will then concentrate on the preclinical studies and the few clinical trials that have been carried out targeting endocannabinoid signaling in three important chronic progressive neurodegenerative disorders (parkinson's disease, huntington's chorea, and alzheimer's disease), as well as in other less well-studied disorders. 2015-12-16 2023-08-13 Not clear
Amandine E Bonnet, Yannick Marchalan. Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease. Aging and disease. vol 6. issue 5. 2015-10-01. PMID:26425394. potential therapeutical contributions of the endocannabinoid system towards aging and alzheimer's disease. 2015-10-01 2023-08-13 Not clear
Amandine E Bonnet, Yannick Marchalan. Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease. Aging and disease. vol 6. issue 5. 2015-10-01. PMID:26425394. a growing number of studies including our own have aimed at the endocannabinoid system and unfolded unique effects of this system on neuroinflammation, neurogenesis and hallmarks of alzheimer's disease and made it a reasonable target in the context of normal and pathological brain aging. 2015-10-01 2023-08-13 Not clear
Iván Manuel, Estíbaliz González de San Román, M Teresa Giralt, Isidro Ferrer, Rafael Rodríguez-Puerta. Type-1 cannabinoid receptor activity during Alzheimer's disease progression. Journal of Alzheimer's disease : JAD. vol 42. issue 3. 2015-08-25. PMID:24946872. the activity of cb1 cannabinoid receptors was studied in postmortem brain samples of alzheimer's disease (ad) patients during clinical deterioration. 2015-08-25 2023-08-13 Not clear
b' A C Pascual, A M Mart\\xc3\\xadn-Moreno, N M Giusto, M L de Ceballos, S J Pasquar\\xc3\\xa. Normal aging in rats and pathological aging in human Alzheimer\'s disease decrease FAAH activity: modulation by cannabinoid agonists. Experimental gerontology. vol 60. 2015-08-19. PMID:25456842.' normal aging in rats and pathological aging in human alzheimer's disease decrease faah activity: modulation by cannabinoid agonists. 2015-08-19 2023-08-13 human
b' A C Pascual, A M Mart\\xc3\\xadn-Moreno, N M Giusto, M L de Ceballos, S J Pasquar\\xc3\\xa. Normal aging in rats and pathological aging in human Alzheimer\'s disease decrease FAAH activity: modulation by cannabinoid agonists. Experimental gerontology. vol 60. 2015-08-19. PMID:25456842.' this modulation leads to a reduced availability of anandamide in alzheimer's disease and to an increased availability of this endocannabinoid in aging. 2015-08-19 2023-08-13 human
Gaurav Bedse, Adele Romano, Angelo M Lavecchia, Tommaso Cassano, Silvana Gaetan. The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 43. issue 4. 2015-08-18. PMID:25147120. the role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in alzheimer's disease. 2015-08-18 2023-08-13 Not clear
Aia Ahmed, M A van der Marck, Gah van den Elsen, Mgm Olde Rikker. Cannabinoids in late-onset Alzheimer's disease. Clinical pharmacology and therapeutics. vol 97. issue 6. 2015-08-12. PMID:25788394. cannabinoids in late-onset alzheimer's disease. 2015-08-12 2023-08-13 Not clear
Jeremy Koppel, Valerie Vingtdeux, Philippe Marambaud, Cristina d'Abramo, Heidy Jimenez, Mark Stauber, Rachel Friedman, Peter Davie. CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. Molecular medicine (Cambridge, Mass.). vol 20. 2015-05-11. PMID:24722782. the endocannabinoid cb2 receptor system has been implicated in the neuropathology of alzheimer's disease (ad). 2015-05-11 2023-08-13 mouse
Nazia Maroof, Srinivasarao Ravipati, Marie Christine Pardon, David A Barrett, David A Kendal. Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the AβPPswe/PS1ΔE9 mouse model of Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 42. issue 1. 2015-05-11. PMID:24844690. reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the aβppswe/ps1Δe9 mouse model of alzheimer's disease. 2015-05-11 2023-08-13 mouse
Nazia Maroof, Srinivasarao Ravipati, Marie Christine Pardon, David A Barrett, David A Kendal. Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the AβPPswe/PS1ΔE9 mouse model of Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 42. issue 1. 2015-05-11. PMID:24844690. alterations in the endocannabinoid system (ecs) are thought to play a role in learning and memory impairments observed in alzheimer's disease (ad). 2015-05-11 2023-08-13 mouse
Matthijs G Bossong, Gerry Jager, Sagnik Bhattacharyya, Paul Alle. Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies. Current pharmaceutical design. vol 20. issue 13. 2015-02-20. PMID:23829369. learning and memory deficits are core symptoms of psychiatric and neurological disorders such as schizophrenia and alzheimer's disease, and may also be related to endocannabinoid dysfunction in these disorders. 2015-02-20 2023-08-12 human
Gaurav Bedse, Adele Romano, Silvia Cianci, Angelo M Lavecchia, Pace Lorenzo, Maurice R Elphick, Frank M Laferla, Gianluigi Vendemiale, Caterina Grillo, Fabio Altieri, Tommaso Cassano, Silvana Gaetan. Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 40. issue 3. 2014-12-17. PMID:24496074. the endocannabinoid system has gained much attention as a new potential pharmacotherapeutic target in various neurodegenerative diseases, including alzheimer's disease (ad). 2014-12-17 2023-08-12 mouse
Pedro González-Naranjo, Natalia Pérez-Macias, Nuria E Campillo, Concepción Pérez, Vicente J Arán, Rocio Girón, Eva Sánchez-Robles, María Isabel Martín, María Gómez-Cañas, Moisés García-Arencibia, Javier Fernández-Ruiz, Juan A Páe. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease. European journal of medicinal chemistry. vol 73. 2014-10-07. PMID:24378710. cannabinoid agonists showing buche inhibition as potential therapeutic agents for alzheimer's disease. 2014-10-07 2023-08-12 Not clear
Jeremy Koppel, Valerie Vingtdeux, Philippe Marambaud, Cristina d'Abramo, Heidy Jimenez, Mark Stauber, Rachel Friedman, Peter Davie. CB₂ receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. Molecular medicine (Cambridge, Mass.). vol 19. 2014-08-08. PMID:24408112. the endocannabinoid cb₂ receptor system has been implicated in the neuropathology of alzheimer's disease (ad). 2014-08-08 2023-08-12 mouse
Ester Aso, Isidre Ferre. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Frontiers in pharmacology. vol 5. 2014-06-24. PMID:24634659. cannabinoids for treatment of alzheimer's disease: moving toward the clinic. 2014-06-24 2023-08-12 Not clear
Slava Rom, Yuri Persidsk. Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 8. issue 3. 2014-02-11. PMID:23471521. while the addictive properties of marijuana, an extract from the cannabis plant, are well recognized, there is growing appreciation of the therapeutic potential of cannabinoids in multiple pathologic conditions involving chronic inflammation (inflammatory bowel disease, arthritis, autoimmune disorders, multiple sclerosis, hiv-1 infection, stroke, alzheimer's disease to name a few), mainly mediated by cb(2) activation. 2014-02-11 2023-08-12 Not clear
Pedro González-Naranjo, Nuria E Campillo, Concepción Pérez, Juan A Páe. Multitarget cannabinoids as novel strategy for Alzheimer disease. Current Alzheimer research. vol 10. issue 3. 2013-11-11. PMID:23369066. multitarget cannabinoids as novel strategy for alzheimer disease. 2013-11-11 2023-08-12 Not clear